Journal of the National Comprehensive Cancer Network

Article	Citations
NCCN News	991
Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial	895
CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!	637
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors	615
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Pha	452
NCCN News	412
PCL22-186: A Potential Biomarker for Radiosensitivity of Squamous Cell Carcinomas in the Head and Neck	348
HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC	339
HSR24-169: Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer	291
HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study	285
CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis	273
HSR24-127: Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native Vs Non-Hispanic White Populations	256
CLO24-055: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis	252
Highlights of the NCCN Oncology Research Program	242
EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care	240
My Report Card	237
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?	231
CLO23-035: Expression of PD-L1 Through Evolution Phase From Pre-Invasive to Invasive Lung Adenocarcinoma	225
HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat	214
CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor	200
CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer	163
CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)	156
EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review	132
HSR24-163: Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed With Hepatocellular Carcinoma	128
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men	126

Oncology Survivorship Care Clinics: Design and Implementation of Survivorship Care Delivery Systems at NCCN Member Institutions	119
BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer	112
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients	110
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment	108
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers	101
Hemithyroidectomy Versus Total Thyroidectomy for Sporadic Medullary Thyroid Cancer: A Chinese Nationwide Large-Scale Cohort Study	95
Empowering Care Teams: Redefining Message Management to Enhance Care Delivery and Alleviate Oncologist Burnout	93
Highlights of the NCCN Oncology Research Program	89
Highlights of the NCCN Oncology Research Program	88
A New Administration and JNCCN	87
NCCN News	84
Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer	83
HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators	79
EPR24-099: Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico	74
YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases	69
CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia	64
Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility	63
HSR25-141: Adolescent and Young Adult Cancer Patients: Our Most Financially Vulnerable Demographic	57
HSR25-181: Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)	57
CLO25-078: Deciphering Risk of Early Biochemical Recurrence in Prostate Cancer Prior to Definitive Therapy	56
EPR25-128: Epidemiology of Olfactory Neuroblastoma: A SEER Stat Review	56
EPR25-138: Glioblastoma Multiforme: A SEER STAT Analysis of Epidemiological, Laterality, and Anatomical Prognostic Indicators	55
Patient-Reported Symptom Complexity and Acute Care Utilization Among Patients With Cancer: A Population-Based Study Using a Novel Symptom Complexity Algorithm and Observational Data	51
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021	50
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology	49
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022	48
QIM24-176: Technology’s Impact on Implementing the NCCN Distress Thermometer in a Community-Based Oncology Clinic	47
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	47
Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary	45
CLO22-059: Chemotherapy Timing and Outcomes in Early Breast Cancer	44
Cancer Screening and Surveillance Testing for Older Adult Cancer Survivors	43
New Treatment Options for Patients With Bladder Cancer	42
Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial	42
NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High-Quality Cancer Care	42
Out in the World Again	42
NCCN News	42
Role of Radiation Therapy in Retroperitoneal Sarcoma	41
Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice	41
Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy	40
QIM23-140: Health Care Satisfaction Among Cancer Patients Undergoing Radiotherapy: A Tunisian Center Experience	38
CLO22-048: Treatment Outcomes of Metastatic Urothelial Cancer on Immune Checkpoint Inhibition	37
Highlights of the NCCN Oncology Research Program	36
Optimizing BTK Inhibition in Waldenström Macroglobulinemia	36
CLO23-059: HDR-ICR Brachytherapy With Solo Anesthesia Administration as a Resource-Effective and Patient-Safe Method in Cancer Cervix	35
Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma	34
CLO23-032: Treatment of HER2+ Breast Cancer: A Retrospective of Disease Prognosis With Loss of HER2 Amplification on Residual Disease After Neoadjuvant Treatment in a Community Hospital Setting	34
Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology	34
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity	33
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial	32
Race- and Age-Related Disparities in Cervical Cancer Mortality	31

Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma	30
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response	29
CLO22-051: Influence of Environmental Temperature on Pathological Complete Response and Overall Survival in Breast Cancer: A National Cancer Database Population-Based Study	28
CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer	28
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study	26
Urinary Circular RNA Panels to Detect HBV-Related Hepatocellular Carcinoma: A Multicenter, Large-Scale, Case-Control Study	26
Hope and Uncertainty in Advanced Cancers	26
Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care	25
EPR25-133: Frequency and Pattern of 30-Day Readmissions in Cancer Patients With C.difficile Infection	25
HSR25-202: Epidemiology and Outcomes of Ventricular Arrhythmias in Patients With Hypercalcemia of Malignancy: A Population-Based Study	25
CRE25-044: A Case Series of Immunotherapy-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis	24
HSR25-166: Linking COVID-Related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients	23
HSR25-151: EPIC Patient Portal Functionality: An Equity Analysis in Vulnerable Cancer Patients	23
HSR25-148: The State of Lung Cancer in Alabama	22
Enhancing Readability of Online Patient-Facing Content: The Role of AI Chatbots in Improving Cancer Information Accessibility	22
NCCN News	21
Integrating Immune Therapies for the Treatment of Multiple Myeloma	21
CGE23-071: Real World Data on the Implementation of a Hereditary Hematological Myeloid Malignancy Workflow: Experience of a Single Academic Medical Center	21
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022	21
QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing	21
BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils	20
NCCN News	20
CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde	20
CLO22-086: A Phase 2, Multi-Arm Study of Anti-CD47 Antibody Magrolimab in Combination With Docetaxel in Patients With Locally Advanced or Metastatic Solid Tumors	20
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology	18
Priorities of Unmet Needs for Those Affected by Colorectal Cancer: Considerations From a Series of Nominal Group Technique Sessions	18
Perioperative Management of Anticoagulation and Antithrombotic Therapy	18
Machine Learning–Based Early Warning Systems for Acute Care Utilization During Systemic Therapy for Cancer	18
Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas	18
Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral	17
Mitigating the Risk of Aberrant Use of Opioids in Patients With Cancer Pain	17
The Future of Geriatric Oncology Research: Moving Toward Interventions and Objective Biomarkers of Aging	17
Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice	17
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022	17
Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer	17
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	17
Disparate Use of Chemoradiation in Elderly Patients With Localized Anal Cancer	17
The Value and Process of Inclusion: Using Sensitive, Respectful, and Inclusive Language and Images in NCCN Content	17
NCCN News	17
Key Performance Indicators and Metrics for the Implementation of an Oral Chemotherapy Adherence Program	16
EPR24-101: Characteristics of Individuals With Early-Onset GI Cancers in the Southeastern US	16
Promising Practices to Reduce the Impact of Drug Shortages on Cancer Care	16
Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia Among Patients With Solid Tumors	16
HSR24-166: Implementation of an Integrated Supportive Care Medicine Consultation Service Within a Gastrointestinal Cancer Clinic: Timeliness of Referrals and Patient Access	16
Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy	15
First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study	15
Changes for JNCCN in 2025	15
HSR24-171: Utilizing Diverse Enrollment to Validate the DELFI Fragmentome Test for Advancing Lung Cancer Screening	15
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL	15
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology	15
NCCN Policy Summit: Cancer Across Geography	15
Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database	15
BIO25-024: Real-Time Clinical Trial Data Library in Non-Small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a Reality With a Fine-Tuned Large La	15
HSR25-153: Patient Preferences and Willingness to Accept Trade-Offs for a Favorable Treatment Response Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	14
QIM25-228: Utilizing Patient and Provider Perspectives in Psycho-Oncology Program Development and Quality Improvement	14
HSR25-190: Clinical Experience With Immunotherapy in Advanced Solid Tumors – Real World Data From India	14
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022	14
BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care	14
HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer	14
YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study	14
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Ma	14
QIM25-230: Enhancing Communication Through Interprofessional Goal Concordant Care Training	14
CLO25-102: Survival Outcomes in Breast Cancer Patients With Diseased Axillary Lymph Nodes: The Role of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.	14
Addressing Racial Inequity in Cancer Care: Self-Awareness Among Oncology Professionals	13
Reaching Populations to Address Disparities in Cancer Care Delivery: Results From a Six-Site Initiative	13
Optimizing First-Line Therapy for Advanced-Stage Classic Hodgkin Lymphoma	13
Erratum	13
Letter to the Editor: T1a 0- to 2-cm Small Renal Masses	13
EPR22-113: Awareness, Utilization, and NCCN Guideline-Adherence to Breast Cancer Risk Management Behavior Among a Community-Based Sample of High-Risk Women	13
EPR22-106: Decelerating Decline and Urban-Rural Differences for Gastrointestinal Cancer Mortality in the United States, 1999-2019	13
CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population	13
NCCN News	12
BPI23-016: Interventional Pain Management in Outpatient Setting for Cancer Patients: A Review of Literature	12
Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer	12
HSR23-121: Assessment of Sustained MRD Negativity and Reversion in Real-World Multiple Myeloma Patients Using NGS (clonoSEQ Assay)	12
BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic	12
EPR23-080: Oral Cancer Screening Among the Rural Indians—A Community Based Prospective Study	12
High-Risk Prevention Programs: Identifying Services for High-Risk Patients	12
CLO23-039: Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma: A Systematic Review	11
Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition	11

Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies	11
CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series	11
HSR24-126: “Share the Fear”: Communication Concerns of Parents With Cancer With Dependent Children for Their Co-Parent: A Qualitative Study	11
Abstracts From the NCCN 2023 Annual Conference	11
Authors’ Reply to the Letter to the Editor by Liu and Kesselheim	11
EPR22-118: Incidence of Herpes Zoster in Immunocompromised Individuals and Zoster Vaccination as an Effective Preventative Strategy	11
BIO22-028: Identification of Gene Expression Signature Associated With Overall Survival in Patients With Non-Small Cell Lung Cancer	11
CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches	10
BPI24-010: Temporary Toilet Lids Minimize Contamination of Bathroom Surfaces With Hazardous Drugs	10
HSR24-150: Real-World Treatment Patterns of Selumetinib Among Patients With Neurofibromatosis Type I and Plexiform Neurofibroma in the United States	10
Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults	10
CRE25-043: Treatment of HER2-Positive Breast Cancer With Leptomeningeal Metastases With Intrathecal Trastuzumab	10
Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study	10
CRE24-038: Neuroendocrine Tumor of the Gallbladder: A Case Report and Literature Review.	10
HSR24-173: Reaching Unmet Needs of Lung Cancer Patients Through Hope Totes and Educational Meetings	10
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model	10
NCCN Guidelines for Central Nervous System Cancers: Updates in the Treatment of Adult Patients With Glioma	10
Highlights of the NCCN Oncology Research Program	10
HSR24-148: Outcome of Positron Emission Tomography–Computed Tomography Staging in Breast Cancer Patients Having Neo-Adjuvant Systemic Therapy	10
Letter to the Editor: Differentiating Between Intentional Versus Unintentional Weight Loss	10
CRE25-041: Pneumocephalus in the Setting of Endometrial Adenocarcinoma: A Case Report	10
Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma	9
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022	9
HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractor	9
Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy	9
Aligning With the National Cancer Plan	9
Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About	9
Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment	9
Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling	8
Incident Cancer Detection During Multiple Waves of COVID-19: The Tsunami After the Earthquake	8
CLO23-040: Electrocardiographic Findings in Cancer Patients Receiving Chemotherapy From the Colombian Coffee Triangle Region	8
BPI22-023: Strategies to Prevent Unplanned Emergency Department (ED) Utilization in the COVID-19 Era	8
CLO23-026: Hydrogel Slope and Optimization of Prostate-Rectal Hydrogel Placement	8
Referral, Uptake, and Outcome of Genetic Counseling and Testing in Patients With Early-Onset Colorectal Cancer	8
NCCN News	8
HSR23-112: Disease Burden and Treatment Patterns in Patients Diagnosed With HER2- Metastatic Gastric/Gastroesophageal Junction Cancer (mG/GEJC)	8
Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer	8
QIM23-133: Aligning NCCN Criteria With Testing Workflows Using a Novel Database Application (Criterion™)	8
NCCN News	8
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma	8
HSR23-113: Patient and Provider Perspectives on How COVID-19 Impacted Melanoma Care Delivery	8
Importance of Family History of Colorectal Carcinoma In Situ Versus Invasive Colorectal Cancer: A Nationwide Cohort Study	8
T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy	7
HSR25-144: Clinical Outcomes for Leukemia Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample	7
CLO25-083: Immune-Related Adverse Events in Women With Early and Advanced Triple-Negative Breast Cancer Treated With Pembrolizumab: A Multi-Center Analysis	7
Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy	7
QIM25-227: Evaluating Dosimetric Differences in Head and Neck Cancer Treatment: A RapidArc Approach With Flattening Filter-Free vs. Filtered Beams	7
Highlights of the NCCN Oncology Research Program	7
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024	7
HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or	7
EPR25-137: Epidemiology and Prognostication of Malignant Glomus Tumor	7
Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series	7
BPI22-016: Leveraging Best Practices in Tobacco Cessation for Cancer Patients: The Fox Chase Cancer Center (FCCC) Case Study	7
Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures	7
EPR24-117: A Comprehensive Examination of Disparities in Metastatic Breast Cancer Incidence: Race, Income and Geography	7
CLO25-070: Effects and Mechanisms of CD16+/-NK Cells on Ovarian Malignant Tumor Cells Platinum-Based Drug Responsiveness in Tumor Microenvironment	7
Optimizing Electronic Secure Messaging to Mitigate Oncologist Burnout	7
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma	6
Failure Doesn’t Feel Good!	6
I Cannot Afford This!	6
HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy	6
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer	6
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology	6
BPI24-013: Microwave Ablation Versus Resection Versus Stereotactic Body Radiation Therapy of Stage IA Non–Small Cell Lung Cancer in US Veterans	6
Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease	6
Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer	6
NCCN Guidelines® Updates: T-Cell Lymphomas	6
HSR22-158: Managing Diabetes Mellitus During Cancer Treatment: The Missing Link to Primary Care	6
HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy	6
NCCN News	6
QIM25-223: Acceptability, Facilitators, and Barriers to the Implementation of Screening and Brief Intervention for Alcohol Counseling in the Oncology Setting	6
Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study	6
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024	6
Use of PARP Inhibitors for Ovarian Cancer	6
HSR22-155: Management of Close/Positive Margins in cSCCHN	6
NCCN News	6
QIM24-178: Managing Pharmaceutical Costs in the Oncology Care Model	6
Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled Cohort	6
BPI24-026: Utilization of ExoDx Prostate Test for Prostate Cancer Risk Stratification in the African American Population	5
Integrating Diversity, Equity, and Inclusion Approaches Into Treatment of Commercial Tobacco Use for Optimal Cancer Care Delivery	5
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology	5
Rurality Status and Cardiovascular Events/Survival in Older Men With Prostate Cancer	5
End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials	5
Advancing Health Equity in Cancer-Related Distress: Lessons Learned From the COVID-19 Pandemic on Leveraging Digital Tools and Future Directions	5
Letter to the Editor: The Role of Skin Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity	5
CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer	5
Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking	5
Lobbying in US Health Care—Lessons From the Field of Oncology	5
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis	5
Erratum to: NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022	5
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers	5
NCCN News	5
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology	5
HSR25-168: Survival Analysis for Early Onset and Very Early Onset Colon Cancer Using National Cancer Database (NCDB) 2004-2021	5
Assessing Equity in Quality Care for Metastatic Pancreatic Cancer	5